Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV PERSERIS — Net revenue

Other product segments

SUBLOCADE
$232M+31.8%
Sublingual & other
$50M-7.4%

Similar metrics at other companies

Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Eli Lilly logo
LLYNet product revenue — Revenue
$18.45B+59.1%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Biogen logo
BIIBProduct revenue, net — Total Revenue
$1.75B+1.5%
BridgeBio Pharma logo
BBIONet product revenue — Revenue
$180.6M+392%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%
Enterprise value$4.86B+242%
P/E18×—
P/S3.5×+2.3×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's perseris — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's PERSERIS — net revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported PERSERIS — net revenue of $5M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's PERSERIS — net revenue changed year-over-year?
Indivior Pharmaceuticals, Inc. 's PERSERIS — net revenue increased by 25.0% year-over-year, from $4M to $5M.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's PERSERIS — net revenue?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's PERSERIS — net revenue has grown at a -6.3% compound annual growth rate (CAGR), from $28M to $23M.
What does PERSERIS — net revenue mean?
This metric represents the total gross sales of a specific pharmaceutical product line after accounting for returns, allowances, and rebates. It serves as a key indicator of the product's market adoption, commercial performance, and contribution to the company's overall revenue stream within the mental health therapeutic area. Tracking this figure allows investors to evaluate the lifecycle stage and competitive positioning of the drug in the marketplace.